Intelligence Feed event · Equity · 2026-09-18

    Eli Lilly posts $27.7B 1H GLP-1 revenue as oral obesity drug Foundayo expands

    Question

    Eli Lilly posts $27.7B 1H GLP-1 revenue as oral obesity drug Foundayo expands

    Direct answer

    Eli Lilly recorded $27.7 billion in first-half 2026 revenue across its flagship GLP-1 products Mounjaro and Zepbound. The company expanded commercial access for its oral obesity treatment Foundayo, securing formulary placement across leading pharmacy benefit managers. Beyond core metabolic franchises, Eli Lilly's newer specialty therapies grew 121% in Q2 2026. The print comes after a roughly 7% pullback in LLY shares over the trailing month, reflecting broader valuation compression across large-cap healthcare stalwarts.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-18
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Eli Lilly posts $27.7B 1H GLP-1 revenue as oral obesity drug Foundayo expands”, revision 1, evidence through 2026-09-18. https://marketontology.com/market-events/2026-09-18/eli-lilly-posts-27-7b-1h-glp-1-revenue-as-oral-obesity-drug-foundayo-expands-87d1ba

    EQUITY
    Eli Lilly posts $27.7B 1H GLP-1 revenue as oral obesity drug Foundayo expands
    Eli Lilly recorded $27.7 billion in first-half 2026 revenue across its flagship GLP-1 products Mounjaro and Zepbound. The company expanded commercial access for its oral obesity treatment Foundayo, securing formulary placement across leading pharmacy benefit managers. Beyond core metabolic franchises, Eli Lilly's newer specialty therapies grew 121% in Q2 2026. The print comes after a roughly 7% pullback in LLY shares over the trailing month, reflecting broader valuation compression across large-cap healthcare stalwarts.
    LLYNVO
    Impact
    72
    SEP 18
    SIG
    85%
    LLYNVO
    Eli Lilly posts $27.7B 1H GLP-1 revenue as oral obesity drug Foundayo expands
    Eli Lilly recorded $27.7 billion in first-half 2026 revenue across its flagship GLP-1 products Mounjaro and Zepbound. The company expanded commercial access for its oral obesity treatment Foundayo, securing formulary placement across leading pharmacy benefit managers. Beyond core metabolic franchises, Eli Lilly's newer specialty therapies grew 121% in Q2 2026. The print comes after a roughly 7% pullback in LLY shares over the trailing month, reflecting broader valuation compression across large-cap healthcare stalwarts.
    → Expanded PBM coverage for oral obesity drug Foundayo defends metabolic franchise cash flows against competing injectable GLP-1 therapies.
    Impact
    Eli Lilly recorded $27.7 billion in first-half 2026 revenue across its flagship GLP-1 products Mounjaro and Zepbound. The company expanded commercial access for its oral obesity treatment Foundayo, securing formulary placement across leading pharmacy benefit managers. Beyond core metabolic franchises, Eli Lilly's newer specialty therapies grew 121% in Q2 2026. The print comes after a roughly 7% pullback in LLY shares over the trailing month, reflecting broader valuation compression across large-cap healthcare stalwarts.
    Affected
    LLYNVO
    Transmission
    Expanded PBM coverage for oral obesity drug Foundayo defends metabolic franchise cash flows against competing injectable GLP-1 therapies.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYprescription volume growth via expanded commercial PBM formulary coverageUp1-4wGLP-1 generated $27.7B in 1H 2026 and oral pill Foundayo gained coverage across major PBMs.
    NVOmarket share competition in oral metabolic therapeutic formulationsMixed1-3mDirect global competitor in GLP-1 and oral weight-loss indications.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    NVOMixed43.24 2026-09-18-7.96%-10.27%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month